Strides Pharma gains on transfer of Bengaluru facility to Syngene
Stelis and Syngene have executed the final agreements to transfer its Unit 3 multi-modal facility in Bengaluru to Syngene with gross consideration adjusted from Rs 702 crore to Rs 617 crore.